ZANTAC
LOE ApproachingNDAORALSYRUP
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC is an oral syrup formulation approved in 1988 as a small-molecule H2-receptor antagonist. The drug's precise mechanism of action and specific indications are not documented in available data, though H2 antagonists typically treat acid-reflux disorders. This legacy product represents a foundational therapeutic class in gastroenterology.
LOE Approaching
Product is in late lifecycle phase with moderate competitive pressure (30/100), indicating reduced team investment and transition focus toward LOE preparation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
Positions on ZANTAC teams are primarily focused on managing commercial decline, ensuring smooth LOE transition, and potentially repositioning for OTC or authorized generic channels. Career growth is limited by the product's mature stage; professionals should expect transition planning and operational efficiency roles rather than expansion or launch activities.
Brand Manager
Worked on ZANTAC at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.